Pharmaceuticals, Biotechnology and Life Sciences
Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug…
Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for combination products, has announced an agreement with Pfeiffer Vacuum Technologies to provide characterization testing of container-closure systems for the biopharma industry.
Clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, Adverum Biotechnologies on Tuesday announced the opening of its new corporate headquarters at one of the largest biotechnology research complexes in the San Francisco Bay Area.
AFFiRiS AG, a clinical-stage biopharmaceutical company developing novel disease-modifying specific active immunotherapies (SAITs) for patients with neurodegenerative diseases, will proceed with the preparations for the planned phase 2 study and confirms its intended initiation in the US and Europe in the second half of 2020.
Hutchison China MediTech Limited said on Friday that it got approval from the China’s authority, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), a Priority Review status to the New Drug Application (NDA) for surufatinib, for the treatment of patients with advanced non-pancreatic neuroendocrine tumors (NET).
#Symbiosis Pharmaceutical Services has invested over £1.5m ($1.9m) during the last year, to expand its sterile biologics manufacturing facility in Scotland, UK by 25%.
Swiss-based Roche’s is buying Spark Therapeutics for of $114.50 per share in cash, total $4.3 billion through its fully owned subsidiary 022019 Merger Subsidiary.
Inceptua, a pharmaceutical company and service partner in comparator sourcing for clinical trials, through early access programs to licensing and commercialization of products, said Wednesday that Stefan Fraenkel, Executive Vice President, and Member of the Executive Leadership Team, is promoted to CEO effective 1 January, 2020.
Pharmaceutical companies have started to embrace a more collaborative way of working as part of a movement to help overcome some of the challenges the industry is facing. Expiring patents and a tight regulatory environment are just some of the issues that are hoped to be resolved through forming partnerships across the industry, and even with competitors.
Synimmune GmbH, a biotechnology company focusing on the development of innovative and effective anti-tumor antibodies for orphan hematopoietic malignancies, presented results of its first-in-human clinical study of FLYSYN, a novel Fc-optimized antibody, for the treatment of acute myeloid leukemia (AML) were presented at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.